Unknown

Dataset Information

0

Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.

ABSTRACT: Lysine-specific demethylase 1 (LSD1/KDM1A) is a promising therapeutic target for the treatment of cancers. Several derivatives of tranylcypromine (trans-2-phenylcyclopropylamine) have been developed as LSD1 inhibitors. One such derivative is S2157; however, this compound has a high hERG channel inhibitory activity and a low microsomal stability, making it unsuitable as a drug candidate. Here, using an in silico hERG inhibition prediction model, we designed, synthesized, and evaluated a novel series of S2157 derivatives characterized by modifications of the benzyloxy and piperazine groups. Among the synthesized derivatives, a compound possessing 2-fluoropyridine and 2,8-diaza-spiro[4.5]decane groups (compound 10) showed the most desirable activities, and its eutomer, S1427, was isolated by the optical resolution of 10. In addition to potent LSD1 inhibitory activity, S1427 exhibited desirable hERG channel inhibition and microsomal stability profiles.

SUBMITTER: Koda Y 

PROVIDER: S-EPMC9109268 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.

Koda Yasuko Y   Sato Shin S   Yamamoto Hirofumi H   Niwa Hideaki H   Watanabe Hisami H   Watanabe Chiduru C   Sato Tomohiro T   Nakamura Kana K   Tanaka Akiko A   Shirouzu Mikako M   Honma Teruki T   Fukami Takehiro T   Koyama Hiroo H   Umehara Takashi T  

ACS medicinal chemistry letters 20220429 5

Lysine-specific demethylase 1 (LSD1/KDM1A) is a promising therapeutic target for the treatment of cancers. Several derivatives of tranylcypromine (<i>trans-</i>2-phenylcyclopropylamine) have been developed as LSD1 inhibitors. One such derivative is <b>S2157</b>; however, this compound has a high hERG channel inhibitory activity and a low microsomal stability, making it unsuitable as a drug candidate. Here, using an <i>in silico</i> hERG inhibition prediction model, we designed, synthesized, and  ...[more]

Similar Datasets

Unknown Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors.
| S-EPMC9077246 | biostudies-literature
Unknown Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
| S-EPMC7125024 | biostudies-literature
Unknown Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i> Growth.
| S-EPMC7841955 | biostudies-literature
Unknown Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.
| S-EPMC5725435 | biostudies-literature
Unknown Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
| S-EPMC7294731 | biostudies-literature
Unknown Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.
| S-EPMC4329595 | biostudies-literature
Unknown Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle Replacement.
| S-EPMC4434479 | biostudies-literature
Unknown Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.
| S-EPMC3720659 | biostudies-literature
Unknown Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.
| S-EPMC5970965 | biostudies-literature
Unknown Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability.
| S-EPMC4277207 | biostudies-literature